In June 2025, Anne Wojcicki won a bankruptcy auction for a company she already ran. Four years earlier, that same company — 23andMe, the DNA-testing business she co-founded in 2006 — had gone public at a $3.5 billion valuation and briefly traded at a $6 billion market cap. By the time she bid on it, it was a defendant in Chapter 11, and she was bidding against a pharmaceutical giant that had already won the first auction outright.

She won the second one. The buyer of record wasn’t Anne Wojcicki, private citizen, or a fund with her name on it — it was TTAM Research Institute, a nonprofit she had formed for exactly this purpose, weeks earlier. The founder didn’t just get her company back. She had to invent a new kind of entity to do it.

A bet that only worked if millions of strangers trusted her with their DNA

23andMe’s premise, when Wojcicki, Linda Avey and Paul Cusenza launched it in 2006, was that a $99 spit kit could tell ordinary people what a genetics lab used to tell only patients and researchers — and that enough of them would opt in to build something like a real-time genetic research database in the process. It worked well enough, well before it worked commercially: by 2013 the FDA had ordered the company to stop marketing its health-risk reports altogether, unconvinced that consumers could parse a genetic risk score without a doctor in the room. 23andMe spent roughly two years rebuilding its regulatory case before the FDA let health reports back on the market.

The company’s real asset was never really the test. It was the database the tests built — millions of customers’ genetic and survey data, the majority of whom had opted into research use, which underwrote a $300 million equity investment and multi-year drug-discovery partnership from GlaxoSmithKline in 2018. That data business, not the one-time $99 kits, was the pitch behind 23andMe’s 2021 debut on the Nasdaq via a SPAC merger with Richard Branson’s VG Acquisition Corp., a deal that valued the company at $3.5 billion and briefly made Wojcicki a self-made billionaire on paper as the stock popped toward a $6 billion market cap on its first trading days.

The single event that broke the trust the business was built on

The database that was 23andMe’s whole thesis was also its single point of failure, and in October 2023 that failure arrived: hackers used credential stuffing — reusing passwords leaked from other breaches — to access accounts belonging to 6.9 million customers, including genetic ancestry data that in some cases named living relatives who had never used the service themselves. It became one of the largest genetic-privacy breaches on record. A coalition of 42 state attorneys general eventually reached a settlement valued at $150 million over the company’s security practices — though bankruptcy’s limited funds mean only about $18 million will actually be distributed among the states — and a separate consumer class action produced a $46.75 million settlement that a bankruptcy court approved in July 2026, nearly three years after the breach and well after the company that caused it had already ceased to exist in its original form.

Revenue never recovered alongside the reputational damage. 23andMe cut its workforce five separate times between 2023 and late 2024, including a round that eliminated roughly 40% of remaining staff and shut down its therapeutics division entirely, taking headcount from over 800 employees to roughly 300.

The board said no, and then there was no board left

By 2024, Wojcicki’s response to the collapsing stock price was to try to take the company private, off the public markets entirely. Her board’s seven independent directors rejected the terms of her proposal as insufficiently financed and not in the interest of outside shareholders — and on September 17, 2024, all seven resigned at once rather than keep negotiating with her, an extraordinary rebuke given that Wojcicki controlled roughly 49% of the company’s voting power through a dual-class share structure. She called the walkout surprising and disappointing in a memo to staff. It did not change the trajectory: six months later, on March 23, 2025, 23andMe filed for Chapter 11 bankruptcy, and Wojcicki resigned as CEO the same day, explicitly to free herself to bid on the company’s assets as an outside party rather than run a sale process she was also trying to win.

Losing the first auction, and refusing to accept it

The bankruptcy court’s first sale process produced a winner in May 2025: Regeneron Pharmaceuticals, the pharmaceutical company, agreed to buy substantially all of 23andMe’s assets — its consumer genetics business, biobank and research operations — for $256 million. Wojcicki had bid too, through a newly formed nonprofit called TTAM Research Institute (an acronym for the company’s own name), and lost.

She did not let the result stand. Represented by the law firm Quinn Emanuel, Wojcicki’s side pushed to reopen the closed auction, then out-bid Regeneron directly: on June 13, 2025, the bankruptcy court confirmed TTAM’s $305 million offer as the winning bid, covering 23andMe’s Personal Genome Service, its research division and its Lemonaid Health telehealth subsidiary. Regeneron, given the chance to counter, declined. The sale closed on July 14, 2025, and 23andMe — the consumer product, the brand, the millions of genetic profiles — became the property of a nonprofit medical research organization that Wojcicki had founded specifically to make that outcome possible, and now runs.

“I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome,” Wojcicki said in a statement announcing the deal.

What founders should actually take from it

The instinct is to read this as a story about a founder’s stubborn loyalty to her own company — nice, but not a strategy anyone else can copy. What’s more specifically useful is what the two auctions reveal about control. Wojcicki’s roughly 49% voting stake wasn’t enough to force a private buyout past an independent board that didn’t trust her price; the board would rather dissolve itself than approve it. But that same conviction, redirected into a bankruptcy court’s asset sale — a process that runs on cash bids and legal standing, not board votes — was enough to beat a company with a market cap thousands of times larger than what she was raising to bid.

The nonprofit structure did real work here too, beyond the optics of “protecting user data from a drugmaker.” A public-benefit nonprofit can commit, in writing, to things a for-profit acquirer structurally can’t promise as credibly — that the genetic data of 15 million-plus customers won’t get sold again to the next distressed buyer down the line. That commitment was plausibly worth real money in a courtroom full of state attorneys general watching the sale for exactly that risk.

The harder lesson is the one before the rescue: none of this was recoverable by better execution once the 2023 breach happened. A trust-based data business survives a security failure only as well as its response to it, and 23andMe’s stock had lost effectively all its value within eighteen months of the breach, board revolt and bankruptcy that followed. Winning the company back was a legal and financial feat. It was not a fix for what broke it in the first place — and the $46.75 million settlement customers are still collecting in 2026 is the reminder that the bill for that failure outlived the company that ran up the tab.

This is an editorial profile assembled from public reporting, court filings, and 23andMe’s and TTAM’s own disclosures. Sources: CNBC — 23andMe files for bankruptcy, Wojcicki steps down as CEO, Axios — 23andMe board resigns en masse, BioPharma Dive — independent board directors resign, FierceBiotech — Regeneron’s $256M bid wins first auction, NBC News — Wojcicki buys back 23andMe for $305 million, TTAM Research Institute — acquisition completion press release, KVIA — Texas AG announces $150 million multistate settlement against 23andMe, HIPAA Journal — $46.75M class action settlement approved, CNN Business — 23andMe cuts 40% of workforce, Forbes — Wojcicki becomes a self-made billionaire after SPAC deal.